Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This study is aimed to compare the pharmacokinetics of levonadifloxacin and its sulfate
metabolite after a single dose of oral WCK 2349 1000 mg in patients with hepatic impairment
and healthy volunteers.